Expression of pRb, p53, p16 and Cyclin D1 and Their Clinical Implications in Urothelial Carcinoma by Lee, Kyungji et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Expression of pRb, p53, p16 and Cyclin D1 and Their Clinical 
Implications in Urothelial Carcinoma
The aim of this study was to assess immunohistochemical expression of p53, pRb, p16, and 
cyclin D1, alone or in combination, as prognostic indicators and to investigate their 
correlation with clinocopathologic features of urothelial carcinoma. Immunohistochemical 
staining for p53, pRb, p16, and cyclin D1 was performed on a tissue microarray from 103 
patients with urothelial carcinoma who underwent radical cystectomy. Of the patient 
samples analyzed, 36 (35%), 61 (59%), 47 (46%) and 30 (29%) had altered expression of 
p53, pRb, p16, and cyclin D1, respectively. Abnormal expression of p53 and pRb correlated 
with depth of invasion (P=0.040 and P=0.044, respectively). Cyclin D1 expression was 
associated with tumor stage and recurrence (P=0.017 and P=0.036, respectively). Altered 
pRb was significantly correlated with overall survival (P=0.040). According to the expression 
pattern of pRb and p53, p53/pRb (altered/normal) had worse survival than p53/pRb 
(normal/altered) (P=0.022). Alteration of all markers had worse survival than all normal 
(P=0.029). As determined by multivariate analysis, tumor stage, lymph node metastasis and 
the combined expression of p53 and pRb are independent prognostic factors. In conclusion, 
immunohistochemical evaluation of cell cycle regulators, especially the p53/pRb 
combination, might be useful in planning appropriate treatment strategies.
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INTRODUCTION
Bladder cancer is the second most common cancer of the geni-
tourinary tract and accounts for about 3.2% of all cancers world-
wide with about 336,000 new cases diagnosed annually (1). In 
Korea, the incidence of bladder cancer has been steadily increas-
ing in recent years; currently, more than 2,200 new cases are di-
agnosed annually (2). Bladder cancer is also the second most 
common malignancy of the genitourinary tract in Korea (3). 
About 95% of bladder tumors are of epithelial origin, and most 
epithelial tumors are urothelial tumors. About 15-30% of all pa-
tients with bladder cancer are initially diagnosed with muscle-
invasive or advanced disease, which has a 50% 5-yr mortality 
rate (4). 
  Stage, lymph node metastasis and grade are well-document-
ed conventional prognostic factors for bladder cancer, but these 
conventional factors are inadequate to successfully predict which 
patients will experience recurrence and/or metastasis (5). The 
identification of adjunctive molecular markers may assist clini-
cal decision-making. Cell proliferation via loss of cell cycle reg-
ulation is the one of the most important molecular and genetic 
changes in bladder carcinoma (6). 
  Herein, we evaluated candidate biomarkers associated with 
the G/S cell cycle checkpoint, including pRb, p53, p16 and cy-
clin D1, in archived paraffin-embedded urothelial carcinoma 
tissue.
MATERIALS AND METHODS
Patients and tissue samples
We analyzed 103 patients who underwent cystectomy for histo-
logically confirmed urothelial carcinoma between January 1996 
and December 2005 at the Kangnam St. Mary’s Hospital and St. 
Mary’s Hospital at the Catholic University of Korea. Approval 
(KC10SISI0155) was obtained from the institutional review board 
of the Catholic University of Korea, Seoul St. Mary’s Hospital. 
Tissue microarray
In order to construct the tissue microarray block, 3 mm-sized 
core biopsies were taken from viable morphologically represen-
tative areas of the paraffin-embedded tumor tissue and were 
assembled on a recipient paraffin block containing 30 biopsies. 
This was carried out using a precision instrument (Micro Digi-
tal Co., Gunpo, Korea). After construction, 5 μm sections were 
cut and the histology was verified by hematoxylin-eosin stain-
ing. Each of the recipient blocks had 3 different control cores. 
The control cores consisted of a normal urinary bladder tissue, a 
normal palatine tonsil, and a breast invasive ductal carcinoma. Lee K, et al.  •  Cell Cycle Regulators in Urothelial Carcinoma
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Imminohistochemistry (IHC)
Five-micrometer sections of the paraffin-embedded tissue arrays 
were cut and mounted on sialanized glass slides. After deparaf-
finization, they were rehydrated in a graded series of alcohol. 
Heat-induced epitope retrival was conducted by immersing 
slides in Coplin jars filled with 10 mM/L citrate buffer (pH 6.0) 
and boiled in a microwave vacuum histoprocessor (RHS-1, Mile-
stone, Pergamo, Italy) at a controlled final temperature of 121°C 
for 15 min and then cooling to room temperature for 15 min. 
After the epitope retrieval, slides were treated with 3% H2O2 in 
methanol for 10 min at room temperature to abolish endoge-
nous peroxidase activity. The tissue arrays were processed in an 
automatic IHC staining machine using standard protocols (Lab 
Vision autostainer, Lab Vision Co., Fremont, CA, USA) with a 
DAKO ChemMate
TM EnVision
TM system (DAKO, Carpinteria, 
CA, USA). The following antibodies were used: pRb (1:200, MAb1, 
Zymed Laboratories Inc., San Francisco, CA, USA), p53 (1:50, 
DO-1, Immunotech, Marseille, Cedex, France), p16 (1:200, E6H4, 
DAKO) and cyclin D1 (1:50, P2D11F11, Novocastra Laborato-
ries Ltd, Newcastle upon Tyne, UK). The immunoreactions was 
developed with 3-3´-diaminobenzidine (DAB, DAKO) for 5 min, 
and then counterstained with Mayer hematoxylin.
  Immunostaining for pRb, p53, p16 and cyclin D1 was inde-
pendently examined by two pathologists. Firstly, as previously 
reported by Im et al. (7), expression levels of pRb, p53, p16 and 
cyclin D1 were determined semi-quantitatively based on the 
fraction of tumor cells showing positive nuclear staining (grade 
0, -10%; grade 1+, 11-25%; grade 2+, 26-50%; grade 3+, 51-75%; 
grade 4+, 76-100%). For the purpose of further analysis, all mark-
ers were placed in one of two categories, altered or normal. Nu-
clear p53 and cyclin D1 were considered altered when more than 
10% of tumor cell nuclei (grade 1+, 2+, 3+, 4+) showed immu-
noreactivity (8, 9) (Fig. 1). Tumor samples with negative (grade 
0) and homogenous strong nuclear positive staining (grade 4) 
for pRb and p16 were considered altered as previously reported 
by Shariat et al. (10-12) and Chatterjee et al. (13) (Fig. 1). 
Statistical analysis
All statistical analyses were performed using the SPSS program 
(version 11.5) for Windows. Survival duration was defined as 
the time from surgery to death attributed to bladder cancer. The 
association between IHC results and clinicopathological vari-
ables was evaluated using the Spearman correlation test and 
chi-squared-test. Survival curves were plotted using the Ka-
plan-Meier method, and statistical significance was deter-
mined by the log-rank test. Univariate analysis and multivariate 
survival analysis were performed using the Cox proportional 
hazards model. P value of <0.05 was considered significant.
RESULTS
Characteristics of the patients
Patients included 93 males and 10 females, and their ages at the 
time of surgery ranged from 27 to 87 yr (mean of 67 yr and me-
dian of 68 yr). Seventeen patients (16.5%) had low-grade urothe-
lial carcinoma and 86 patents (83.5%) had high-grade urothelial 
Fig. 1. Immunohistochemical expression. (A, B) pRb strong homogenous positive and negative (pRb, ×400), (C, D) p16 homogenous positive and negative (p16, ×400), (E) p53 
positive (p53, ×400), (F) cyclin D1 positive (Cyclin D1, ×400). 
A
D
B
E
C
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carcinoma. Of the total patient group, 4 patients (3.9%), 12 pa-
tients (11.7%), 28 patients (27.2%), 26 patients (25.2%), and 33 
patients (32%) were stage 0, 1, 2, 3, and 4, respectively. Twenty-
nine patients (29.9%) had lymph node metastasis at cystecto-
my. Through the review of whole slides, urothelial carcinoma in 
situ was observed in 24 cases (23.3%). Median length of follow-
up was 31.5 months (range 2-133 months). Within the observa-
tion period, a total of 46 patients died from cancer-related causes. 
Clinical characteristics of all 103 patients are summarized in 
Table 1. Univariate survival analysis revealed that stage, lymph 
node metastasis, and depth of invasion were significantly asso-
ciated with overall survival (P=0.001, P=0.037, and P=0.038, re-
spectively). However, all factors were not statistically significant-
ly associated with time to recurrence. 
IHC for pRb, p53, p16 and cyclin D1 
A total of 42 (40.8%), 24 (23.3%), 23 (22.3%), 9 (8.7%) and 5 (4.9 
%) tumors had 0, 1+, 2+, 3+, 4+ staining for p16, respectively. By 
classifying tumors as having normal (1+, 2+, 3+) or altered (0, 
4+) expression of p16, we considered 53% of tumors as wild-type 
expression and 47% of tumors as altered expression. A total of 
51 (49.5%), 20 (19.4%), 9 (8.7%), 13 (12.6%) and 10 (9.7%) tumors 
had 0, 1+, 2+, 3+, and 4+ staining for pRb, respectively. By classi-
fying tumors as having altered (0, 4+) or normal (1+, 2+, 3+) ex-
pression of pRb, we considered 41% of tumors as normal expres-
sion and 59% of tumors as altered expression. A total of 73 (70.9 
%), 10 (9.7%), 12 (11.7%), 8 (7.8%), and 0 (0%) tumors had 0, 1+, 
2+, 3+, and 4+ staining for cyclin D1, respectively. By classifying 
tumors as having normal (0) or altered (1+, 2+, 3+, 4+) expres-
sion of cyclin D1, we considered 71% of tumors as negative ex-
pression and 29% of tumors as altered expression. A total of 51 
(49.5%), 5 (4.9%), 16 (15.5%), 12 (11.7%), and 19 (18.4%) tumors 
had 0, 1+, 2+, 3+, and 4+ staining for p53, respectively. By classi-
fying tumors as having normal (0) or altered (1+, 2+, 3+, 4+) ex-
pression of p53, we considered 65% of tumors as negative ex-
pression and 35% of tumors as altered expression. 
Correlation between the cyclin D1, p16, p53 and pRb
There was a significant relationship between expression of pRb 
and cyclin D1 (P=0.029 and r=0.215) and between expression 
of p16 and p53 (P=0.036 and r=0.207). There was a significant 
inverse relationship between expression of cyclin D1 and p16 
(P=0.001 and r=-0.320) (Table 2). 
Association with the clinicopathological parameters
We tested for correlations between the expression of pRb, p53, 
p16 and cyclin D1 and clinicopathological parameters, such as 
depth of invasion, lymph node metastasis, tumor stage, tumor 
grade, presence of urothelial carcinoma in situ (UCIS) compo-
Table 1. Univariate analysis for overall survival and recurrence-free survival in 103 
urothelial carcinoma
Risk factors
Overall survival
Recurrence-
free survival
P P
Gender
   Female
   Male
10 (9.7%)
93 (90.3%)
0.343 0.367
Age (yr)
   <65
   ≥65
72 (69.9%)
31 (30.1%)
0.612 0.148
Grade
   Low
   High
17 (16.5%)
86 (83.5%)
0.503 0.158
Lymph node status
   N0
   N1, N2
68 (70.1%)
29 (29.9%)
0.037 0.741
Depth of invasion
   Ta
   T1
   T2
   T3
   T4
4 (3.9%)
12 (11.7%)
33 (32.0%)
44 (42.7%)
10 (9.7%)
0.038 0.829
Tumor stage
   0
   I
   II
   III
   IV
4 (3.9%)
12 (11.7%)
28 (27.2%)
26 (25.2%)
33 (32%)
0.001   0.3567
CIS
   Absent
   Present
79 (76.7%)
24 (23.3%)
0.096 0.311
Recurrence
   Absent
   Present
90 (87.4%)
13 (12.6%)
<0.001 -
P value obtained by log-rank test. 
CIS, carcinoma in situ.
Table 2. Association analyses of pRB, p53, p16 and cyclin D1
p53 p16 cyclin D1
pRB 0.014/0.890 -0.066/0.507  0.215/0.029
p53 -  0.207/0.036 -0.067/0.504
p16 - -  -0.320/0.001
r value/P value. Fig. 2. Overall survival curves according to pRb status (P value from log rank test). 
S
u
r
v
i
v
a
l
 
r
a
t
e
Months after surgery
pRb normal
pRb altered
P=0.040
0  20  40  60  80  100  120
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0Lee K, et al.  •  Cell Cycle Regulators in Urothelial Carcinoma
1452   http://jkms.org DOI: 10.3346/jkms.2010.25.10.1449
nent and recurrence (Table 3). Altered expression of cyclin D1 
was associated with recurrence and higher tumor stage (P=0.036 
and P=0.017, respectively). Altered expression of pRb and p53 
correlated significantly with depth of tumor invasion (P=0.044 
and P=0.040, respectively). There was no specific correlation 
between the expression of p16 and these clinicopathologic pa-
rameters. Kaplan-Meier univariate analysis demonstrated worse 
survival with altered expression of pRb (P=0.040) (Fig. 2). Altered 
expression of p53, p16 and cyclin D1 did not have a significant 
impact on patient survival time (P=0.123, P=0.804, P=0.741, re-
spectively), although mean survival time with altered expression 
of cyclin D1 was reduced (data not shown). Evaluation of the 
combined status of markers, which included six possible com-
binations (pRb/p53, pRb/p16, pRb/cyclin D1, p53/p16, p53/cy-
clin D1, and p16/cyclin D1) revealed that only pRb/p53 had a 
statistically significant impact on overall patient survival (P=0.011). 
We analyzed overall survival time with respect to the expression 
pattern of pRb and p53 (Table 4). This analysis indicates that 
patients whose tumors had pRb/p53 (altered/normal) expres-
sion had worse survival than those whose tumors had pRb/p53 
(normal/altered) expression (P=0.022) (Fig. 3). We also analyzed 
overall survival time with respect to the number of altered mark-
ers (i.e. none, one, two, three, or four altered). We found that pa-
tients whose tumors had altered expression of all four markers 
had worse survival than those whose tumors had altered expres-
sion of none (P=0.029) (Fig. 4). We also found that patients whose 
tumors had altered expression of two markers appeared to have 
Table 3. Expression of p53, pRb, p16, cyclin D1 associated with clinicopathologic characteristics
Characteristics
Patients
Frequency (%)
p53 pRB p16 cyclin D1
Altered P Altered P Altered P Altered P
Total 103 36 (35%) - 61 (59%) - 47 (46%) - 30 (29%) -
Gender
   Female
   Male
 10 (9.7%)
   93 (90.3%)
  4
32
0.725 55
  6
0.958 43
  4
0.707 26
  4
0.426
Age (yr)
   <65
   ≥65
   72 (69.9%)
   31 (30.1%)
25
11
0.941 40
21
0.248 36
11
0.175 18
12
0.160
Grade
   Low
   High
   17 (16.5%)
   86 (83.5%)
  4
32
0.280 13
48
0.113 10
37
0.232   8
22
0.075
Lymph node status
   N0
   N1, N2
   68 (70.1%)
   29 (29.9%)
24
10
0.939 40
18
0.765 29
14
0.609 21
  4
0.078
Depth of invasion
   Ta,Tis, T1
   T2, T3, T4
   16 (15.5%)
   87 (84.5%)
  2
34
0.040 13
48
0.044
*
  5
42
0.209   4
26
0.693
Tumor stage
   0
   I
   II
   III
   IV
   4 (3.9%)
   12 (11.7%)
   28 (27.2%)
   26 (25.2%)
33 (32%)
  0
  2
10
11
13
0.306   3
10
14
13
21
0.242   2
  3
13
15
14
0.361   0
  4
  9
13
  4
0.017
CIS
   Absent
   Present
   79 (76.7%)
   24 (23.3%)
29
  7
0.497 48
13
0.565 38
  9
0.361 25
  5
0.307
Recurrence
   Absent
   Present
   90 (87.4%)
   13 (12.6%)
32
  4
0.735 52
  9
0.432 39
  8
0.218 23
  7
0.036
Survival
†
   No. of patients  
   died
   Time to event, (mon) 
   Median
   95% CI
-
-
19
60.3
43-77.4
0.123 32
63.1
49-77
0.040 20
75.9
46-106
0.804 14
76
7.3-144
0.741
P value obtained by Pearson’s chi-square test.
*Fisher’s exact test; 
†P values are the results from log-rank test.
CIS, carcinoma in situ; CI, confidence interval.
Table 4. Overall survival time according to p53 and pRb status
Status No.
Survival time 
(months) 
(mean±SE)
P value 
(vs. pRb/p53, 
altered/normal)
pRb/p53 (altered/normal) 29   90.1±10.5 -
pRb/p53 (altered/altered)  37 70.1±9.1 0.258
pRb/p53 (normal/normal)  12   75.7±13.3 0.741
pRb/p53 (normal/altered)  25   52.9±10.3  0.022*
*Log rank test, P<0.05.Lee K, et al.  •  Cell Cycle Regulators in Urothelial Carcinoma
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decreased survival compared to those whose tumors had altered 
expression of only one marker; however, this observation was 
of borderline statistical significance (P=0.052). We performed 
Cox multivariate analysis with various clinicopathologic vari-
ables (Table 5). Tumor stage, lymph node metastasis and the 
combined expression of pRb and p53 were identified as inde-
pendent prognostic factors. 
DISCUSSION
The prediction of which superficial bladder tumors will recur or 
progress and which advanced tumors will metastasize and prove 
fatal to the patient remains a substantial challenge to be address-
ed in bladder cancer treatment. Despite great advances in our 
understanding of urinary bladder carcinogenesis, attempts to 
identify molecular prognostic or predictive factors other than 
the conventional clinical indicators, such as tumor stage and 
grade, have been largely unsuccessful. Molecular changes in 
bladder tumors involve three main mechanisms: chromosomal 
Table 5. Cox multivariate analysis in urothelial carcinoma 
Risk factors Hazard ratio 95% Confidence interval P value
Tumor stage 1.622 1.00 2.62 0.002*
Lymph node metastasis 0.270 0.08 0.91 0.035*
Combined expression of
   pRb and p53  2.105 1.01 4.35 0.044*
Age (yr) 1.021 0.48 2.13 0.955
Sex 0.806 0.23 2.82 0.736
Grade 1.311 0.50 3.43 0.581
p53 0.632 0.21 1.868 0.407
pRb 1.686 0.57 4.05 0.341
p16 1.035 0.53 2.00 1.035
CyclinD 1.977 0.92 4.23 1.977
*P<0.05.
Fig. 3. Overall survival curves according to combined p53 and pRb status (P value 
from log rank test).
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Fig. 4. Overall survival curves according to the number of altered markers (P value 
from log rank test).
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alteration (the initial event in carcinogenesis), tumor prolifera-
tion due to loss of cell cycle regulation, and metastasis aided by 
processes such as angiogenesis and the loss of cell adhesion (6). 
  Aberrations in G1/S regulatory proteins are common in vari-
ous tumors, and aberrant expression of cyclin D1 and cyclin E, 
down-regulation of p16 and p27, and mutation of the Rb and p53 
genes have been frequently observed in several types of cancer. 
Therefore, it has been suggested that G1/S defects might be oblig-
atory for tumor development (14). Perhaps because of multiple 
redundant pathways that exist to stimulate downstream effec-
tors, there are inconsistent results in the literature concerning 
the use of a single marker of cell cycle regulation as a prognostic 
factor in urothelial carcinoma (15). Therefore, several studies 
have suggested the possibility of cooperative effect involving 
multiple cell cycle regulators (10, 11, 13, 16). 
  In Korea, prognostic significance of p53, p21 and pRb in uro-
thelial carcinoma was reported by Cho et al. (17). They analyzed 
the relationship between recurrence and progression and the 
results of immunostaining in a T1G3 bladder cancer. Any single 
marker did not correlate with tumor recurrence or progression. 
A combination of altered immunostaining for p53/p21/pRb (+/ 
-/-) correlated with progression but not with recurrence. But, it 
included only 30 pTl high grade urothelial carcinomas without 
survival analysis. Despite marked differences in the prognosis 
of pT1 and pT2-4 cancers, these tumors are highly similar on the 
genetic level (18, 19). It could be expected, that similar genetic 
alterations might be prognostically relevant in all stages. In this 
present study, we included early and advanced carcinoma and 
found that the combined expression of pRb and p53 was an in-
dependent prognostic factor, and patients whose tumors had 
altered expression of all four markers had significantly worse 
survival compared to those whose tumors had altered expres-
sion of none. Patients whose tumors had altered expression of Lee K, et al.  •  Cell Cycle Regulators in Urothelial Carcinoma
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two markers appeared to have diminished survival compared 
to those whose tumors had altered expression of one marker, but 
this observation was of borderline statistical significance. The 
results of our study support the hypothesis that cell cycle regu-
lators synergistically affect the progression of urothelial carci-
noma.
  Out of all four markers, only pRb had a significant impact on 
patient survival time in our study. Expression of pRb was altered 
in 59% of cases, which is slightly higher than the 50% of cases 
reported by Cote et al. (8) and 55% of cases reported by Chatter-
jee et al. (13). Previous reports considered negative or strong 
positive (>50%) staining as altered pRb expression because it 
has been shown that overexpression of pRb in bladder cancer is 
also indicative of dysfunctional pRb status (8). Absence of pRb 
reactivity is indicative of loss of gene expression, generally through 
mutation (20), and pRb overexpression reflects an alteration in 
the Rb pathway resulting in loss of several cyclin dependent ki-
nase inhibitors. Therefore both loss and overexpression of pRb 
and p16 were considered altered (8, 21). 
  We modified these criteria. Negative or strong positive (>75%) 
staining was considered to be altered expression of pRb. Because 
we used microarray tissue blocks, we evaluated limited areas of 
tumor compared to previous reports. Although stricter criteria 
was applied, expression of pRb was not significantly different 
from that found in other studies. 
  Altered expression of all four markers, regardless of patholog-
ic stage, correlated with decreased survival compared to nor-
mal expression. This finding, therefore, suggests that multiple 
genetic defects affect the progression and metastasis of urothe-
lial carcinoma.
  There are two distinct precursor lesions to invasive urothelial 
carcinoma: non-invasive papillary tumors (NIPT) and flat non 
invasive urothelial carcinoma (CIS) (22, 23). Whether CIS was 
present or not (CIS present vs. CIS absent) and whether NIPT 
was present or not (NIPT present vs. NIPT absent), there was 
no significant difference in the status of cell cycle markers (data 
not shown). However, it was a limited result because precursor 
lesions were not detected in some cases. Generally, in about one 
half of individuals with invasive bladder cancer, the tumor has 
already invaded the bladder wall. At the time of presentation, 
no precursor lesions can be identified because the high-grade 
invasive component extensively replaces normal structure and 
appears as a large ulcerated mass. 
  There was a significant correlation between the expression of 
certain markers (pRb and cyclin D1, p16 and p53, cyclin D1 and 
p16). This suggests a close relationship between these pairs of 
cell cycle regulators. However, these combinations of markers 
demonstrated no significant association with survival or clini-
copathologic factors. It is well known that high expression of p16 
can lead to loss of the pRb protein, and it has been reported that 
these two factors are inversely correlated in urothelial carcinoma 
(10). Benedict et al. (21) reported there was relationship between 
LOH at 9p21 ( the locus of the MTS-1/INK 4a gene encoding for 
p16) and/or homozygous deletions/mutations within the MTS-
1 gene and p16 or pRb status as determined by immunohisto-
chemistry. They suspected that the immunohistochemical re-
sults of p16 could be the reflection of the genetic alteration sta-
tus. Our results demonstrated an inverse relationship between 
expression of p16 and pRb, but this correlation was not statisti-
cally significant.
  In conclusion, analysis of cell cycle regulators provides prog-
nostic information in addition to that which can be derived from 
well-known prognostic factors, such as grade and stage. There-
fore, immunohistochemical evaluation of cell cycle regulators, 
especially the p53/pRb combination, should be used as a pre-
dictive tool and might provide clinicians with useful informa-
tion to determine treatment strategy.
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